According to the Complaint, Inotiv, Inc. purports to be a contract research organization which provides nonclinical and analytical drug discovery and development services and research models and related products and services. On September 21, 2021, Inotiv announced the acquisition of Envigo RMS, LLC. On November 5, 2021, Inotiv completed the acquisition of Envigo which is now a direct, wholly owned subsidiary of Inotiv.

The Complaint alleges Defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose: (1) Envigo and Inotiv’s Cumberland, Virginia facility engaged in widespread and flagrant violations of the Animal Welfare Act (“AWA”); (2) Envigo and Inotiv’s Cumberland Facility continuously violated the AWA; (3) Envigo and Inotiv did not properly remedy issues with regards to animal welfare at the Cumberland Facility; (4) as a result, Inotiv was likely to face increased scrutiny and governmental action; (5) Inotiv would imminently shut down two facilities, including the Cumberland Facility; (6) Inotiv did not engage in proper due diligence; and (7) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

The Court issued an Order appointing Lead Plaintiff and Counsel on September 12, 2022. Lead Plaintiff filed an amended Complaint on November 14. Lead Plaintiff re-filed the amended Complaint on November 23.

Defendants filed a Motion to Dismiss the amended Complaint on January 27, 2023. On March 29, 2024, the Court issued an Order denying Defendants' Motion to Dismiss.